Clinical Trials, Phase I as Topic
"Clinical Trials, Phase I as Topic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Works about studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the U.S. and in other countries.
Descriptor ID |
D017321
|
MeSH Number(s) |
E05.318.760.250.500.200 N05.715.360.775.088.500.200 N06.850.520.450.250.250.200
|
Concept/Terms |
Microdosing Trials, Human- Microdosing Trials, Human
- Human Microdosing Trial
- Microdosing Trial, Human
- Trial, Human Microdosing
- Trials, Human Microdosing
- Human Microdosing Trials
|
Below are MeSH descriptors whose meaning is more general than "Clinical Trials, Phase I as Topic".
Below are MeSH descriptors whose meaning is more specific than "Clinical Trials, Phase I as Topic".
This graph shows the total number of publications written about "Clinical Trials, Phase I as Topic" by people in this website by year, and whether "Clinical Trials, Phase I as Topic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2003 | 0 | 1 | 1 |
2007 | 0 | 1 | 1 |
2008 | 0 | 1 | 1 |
2009 | 0 | 1 | 1 |
2012 | 0 | 1 | 1 |
2014 | 0 | 2 | 2 |
2015 | 1 | 0 | 1 |
2016 | 1 | 2 | 3 |
2017 | 0 | 2 | 2 |
2018 | 1 | 0 | 1 |
2019 | 1 | 2 | 3 |
2020 | 1 | 1 | 2 |
2021 | 0 | 2 | 2 |
2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Clinical Trials, Phase I as Topic" by people in Profiles.
-
Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials. Lancet. 2022 08 13; 400(10351):512-521.
-
Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models. Clin Cancer Res. 2022 03 15; 28(6):1229-1239.
-
Reversible HER2 antibody-drug conjugate-induced ocular toxicity. Can J Ophthalmol. 2022 04; 57(2):118-126.
-
Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study. Gynecol Oncol. 2021 05; 161(2):512-515.
-
Clinical Impact of Autologous Cell Therapy on Hypoplastic Left Heart Syndrome After Bidirectional Cavopulmonary Anastomosis. Semin Thorac Cardiovasc Surg. 2021; 33(3):791-801.
-
Accelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis. Arthritis Care Res (Hoboken). 2020 02; 72(2):233-242.
-
Jupiter microtubule-associated homolog 1 (JPT1): A predictive and pharmacodynamic biomarker of metformin response in endometrial cancers. Cancer Med. 2020 02; 9(3):1092-1103.
-
Recent insights into apoptosis and toxic autophagy: The roles of MDA-7/IL-24, a multidimensional anti-cancer therapeutic. Semin Cancer Biol. 2020 11; 66:140-154.
-
Identification of high-risk drugs related to chemotherapy-induced peripheral neuropathy?in Cancer Therapy Evaluation Program-sponsored phase I trials. Eur J Cancer. 2019 07; 115:111-119.
-
Consideration of older patients for enrollment in phase 1 clinical trials: Exploring treatment related toxicities and outcomes. Gynecol Oncol. 2018 04; 149(1):28-32.